An indole derivative of Ursolic acid, inhibits RANKL-induced osteoclast differentiation via modulating the Nrf2 and NFATc1/c-Fos axis: Targeting oxidative stress and osteoclastogenesis in managing rheumatoid arthritis

Rheumatoid arthritis (RA) encapsulates chronic autoimmune pathology, characterised by dysregulated immune responses that drive progressive joint destruction and systemic complications. Central to this process is aberrant osteoclast activation driven by RANKL-RANK signalling, which drives excessive bone resorption. In this context, we evaluated UA-1, an indole derivative of ursolic acid. Ursolic acid is a phytochemical known for its anti-arthritic properties with limited clinical applicability (BCS class IV), which drives the need for derivatization. In our recent study, UA-1 showed improved anti-inflammatory potential in comparison to ursolic acid, which may be attributed to its improved physicochemical properties. These results prompted us to evaluate UA-1's anti-arthritic potential both in vitro using RANKL-stimulated osteoclastogenesis in RAW 264.7 macrophages and in vivo using the CIA model. UA-1 significantly reduced the levels of pro-osteoclastogenic cytokines, thereby alleviating subsequent downstream osteoclast differentiation, as corroborated by the decreased expression of osteoclast-specific markers (TRAP, CTSK, MMPs). It also modulated key signalling pathways, including NF-κB, MAPK, and JAK/STAT. Additionally, UA-1 inhibited the key adaptor protein TRAF6 and downregulated the NFATc1/c-Fos axis, major transcription factors involved in osteoclastogenesis. Furthermore, UA-1 also enhanced the antioxidant levels by modulating the NRF-2-mediated antioxidant pathway. Additionally, in the CIA model using C57BL/6, UA-1 alleviated disease markers and reduced pro-inflammatory cytokines, while minimizing joint damage as evidenced by H&E and picrosirius red staining. Overall, the results suggest the potential efficacy of UA-1 in managing RA, given its pronounced suppression of inflammation, oxidative stress and osteoclastogenesis.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2025-11-25
DOI
https://doi.org/10.1016/j.biopha.2025.118801
Citations
1
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
1.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An indole derivative of Ursolic acid, inhibits RANKL-induced osteoclast differentiation via modulating the Nrf2 and NFATc1/c-Fos axis: Targeting oxidative stress and osteoclastogenesis in managing rheumatoid arthritis

Ramajayan Pandian, Boobalan Gopu, Bhavna Vij, Zabeer Ahmed et al.
1 citations
Biomedicine & Pharmacotherapy
Rheumatoid Arthritis Research and Therapies
1.67
article

An indole derivative of Ursolic acid, inhibits RANKL-induced osteoclast differentiation via modulating the Nrf2 and NFATc1/c-Fos axis: Targeting oxidative stress and osteoclastogenesis in managing rheumatoid arthritis

Ramajayan Pandian, Boobalan Gopu, Bhavna Vij, Zabeer Ahmed, Gurleen Kour, Jasha Momo H. Anãl, Rupali Choudhary, Sweta, Asha Bhagat
article en
1 citations

Abstract

Rheumatoid arthritis (RA) encapsulates chronic autoimmune pathology, characterised by dysregulated immune responses that drive progressive joint destruction and systemic complications. Central to this process is aberrant osteoclast activation driven by RANKL-RANK signalling, which drives excessive bone resorption. In this context, we evaluated UA-1, an indole derivative of ursolic acid. Ursolic acid is a phytochemical known for its anti-arthritic properties with limited clinical applicability (BCS class IV), which drives the need for derivatization. In our recent study, UA-1 showed improved anti-inflammatory potential in comparison to ursolic acid, which may be attributed to its improved physicochemical properties. These results prompted us to evaluate UA-1's anti-arthritic potential both in vitro using RANKL-stimulated osteoclastogenesis in RAW 264.7 macrophages and in vivo using the CIA model. UA-1 significantly reduced the levels of pro-osteoclastogenic cytokines, thereby alleviating subsequent downstream osteoclast differentiation, as corroborated by the decreased expression of osteoclast-specific markers (TRAP, CTSK, MMPs). It also modulated key signalling pathways, including NF-κB, MAPK, and JAK/STAT. Additionally, UA-1 inhibited the key adaptor protein TRAF6 and downregulated the NFATc1/c-Fos axis, major transcription factors involved in osteoclastogenesis. Furthermore, UA-1 also enhanced the antioxidant levels by modulating the NRF-2-mediated antioxidant pathway. Additionally, in the CIA model using C57BL/6, UA-1 alleviated disease markers and reduced pro-inflammatory cytokines, while minimizing joint damage as evidenced by H&E and picrosirius red staining. Overall, the results suggest the potential efficacy of UA-1 in managing RA, given its pronounced suppression of inflammation, oxidative stress and osteoclastogenesis.

Biomedicine & PharmacotherapyVol. 193
Indian Institute of Integrative Medicine (IN), Academy of Scientific and Innovative Research (IN)
Openalex Percentile: Top 12%
Rheumatoid Arthritis Research and Therapies
1.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.